Loading
A phase 3 trial of Paltusotine in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by Crinetics Pharmaceuticals Inc., now recruiting.
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen is a phase 3 interventional study registered as NCT07087054 by Crinetics Pharmaceuticals Inc., with 141 participants planned, started 2025-11-19 and due to reach its primary completion in 2027-08. Interventions recorded: Paltusotine and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Crinetics Pharmaceuticals, Neuroendocrine tumours and the tag pipeline.
Shares Crinetics Pharmaceuticals and the tag pipeline.
Shares Small intestinal neuroendocrine tumours, Neuroendocrine tumours and the tag pipeline.
Shares Small intestinal neuroendocrine tumours, Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Small intestinal neuroendocrine tumours, Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/